Objective: To investigate the expression of CD56 in multiple myeloma (MM) cells and its relationship between extramedullary disease and extramedullary relapse.
Methods: Clinical data of 99 patients with MM treated in our hospital from January 2015 to December 2019 was retrospectively analyzed. The patients were divided into positive group and negative group according to the expression of CD56. The relationship between CD56 and multiple myeloma extramedullary disease, extramedullary relapse was analyzed.
Results: Among 99 newly diagnosed patients with MM, the positive rate of CD56 was 65%, and the incidence of extramedullary disease of patients in the CD56 positive group was lower than that in the CD56 negative group (17.19% vs 48.57%) (P<0.01). Meanwhile, the incidence of extramedullary relapse of patients in the CD56 positive group was lower than that in the CD56 negative group (1.56% vs 34.29%) (P<0.01).
Conclusion: CD56 is highly expressed in MM, and its low expression is associated with the occurrence of extramedullary disease and extramedullary relapse, which suggests that CD56 may be an important indicator for predicting the occurrence of extramedullary disease and extramedullary relapse.
题目: 多发性骨髓瘤肿瘤细胞CD56表达与髓外病变和髓外复发的关系.
目的: 探讨初诊多发性骨髓瘤（MM）患者瘤细胞表面CD56表达与髓外病变和髓外复发的关系.
方法: 回顾性分析2015年1月至2019年12月就诊于甘肃省人民医院血液科及肿瘤内科的初诊MM患者的临床资料99例，依据CD56表达情况将患者分为CD56+和CD56-组，分析其与多发性骨髓瘤髓外疾病和髓外复发的关系.
结果: 99例初诊MM患者CD56+表达率65%，CD56+组髓外病变发生率低于CD56-组（17.19% vs 48.57%，P<0.01）。同时CD56+组髓外复发发生率低于CD56-组（1.56% vs 34.29%，P<0.01）.
结论: CD56在MM中表达较高，其低表达与髓外病变发生和髓外复发相关，CD56可能是预测MM发生髓外病变和髓外复发的重要指标.